Neuro /macdonald/taxonomy/term/988/all en AI analysis of healthcare records reveals key factors in autism diagnosis /macdonald/channels/news/ai-analysis-healthcare-records-reveals-key-factors-autism-diagnosis-364500 <b>Scientists argue the criteria we use for diagnosing autism may need revision</b> <p>Without clear and effective biological tests for autism based on genes, brain or blood measurements, diagnosis today still largely depends on clinical assessment. The standard way of doing this is by observing how the individual fits the criteria for autism listed in gold standard manuals like the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).</p> Wed, 26 Mar 2025 15:23:21 +0000 admin 62633 at /macdonald Six principal investigators from The Neuro receive CIHR grants /macdonald/channels/news/six-principal-investigators-neuro-receive-cihr-grants-363535 Projects include important research on Parkinson’s, glioblastoma and dementia <p> </p> Mon, 10 Feb 2025 18:44:57 +0000 admin 62644 at /macdonald Prescribing anti-swelling drug reduces immune response weeks after last dose /macdonald/channels/news/prescribing-anti-swelling-drug-reduces-immune-response-weeks-after-last-dose-363884 <b>Mapping immune cell diversity reveals dexamethasone’s impact on brain cancer immunotherapy</b> <p> </p> <p>Swelling caused by brain cancer is a problem that can lead to serious side effects and even death. While controlling swelling is important, a new study shows that a commonly prescribed anti-swelling drug suppresses the immune system for weeks after dosage, inhibiting the body’s ability to fight the cancer.</p> Wed, 26 Feb 2025 16:05:58 +0000 admin 62642 at /macdonald Project to create AI model for ALS receives Génome Québec funding /macdonald/channels/news/project-create-ai-model-als-receives-genome-quebec-funding-364258 <b>$400,000 will fuel public-private collaboration to discover new disease biomarkers</b> <p> </p> <p>A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU’s program manager, will receive $400,000 in support from Génome Québec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.</p> Mon, 17 Mar 2025 15:29:17 +0000 admin 62639 at /macdonald